Streetbeat News

Analyst Ratings

CHKP

BMO Capital analyst Keith Bachman maintains a 'Market Perform' rating on Check Point Software (NASDAQ:CHKP) and raises the price target from $133 to $140.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 1:53 pm

KO

JP Morgan analyst Andrea Teixeira maintains an Overweight rating on Coca-Cola (NYSE:KO) and raises the price target from $67 to $71.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 1:52 pm

CB

BMO Capital analyst Michael Zaremski maintains a Market Perform rating on Chubb (NYSE:CB) and raises the price target from $200 to $210.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 1:52 pm

AEM

BMO Capital analyst Andrew Kaip maintains an 'Outperform' rating on Agnico Eagle Mines (NYSE:AEM) and raises the price target from $64 to $67.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 1:51 pm

CMG

JP Morgan analyst John Ivankoe maintains a Neutral rating on Chipotle Mexican Grill (NYSE:CMG) and raises the price target from $2000 to $2050.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 1:50 pm

CASY

JP Morgan analyst John Royall maintains a Neutral rating on Casey's General Stores (NASDAQ:CASY) and raises the price target from $211 to $231.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 1:49 pm

BA

JP Morgan analyst Seth Seifman maintains an Overweight rating on Boeing (NYSE:BA) and raises the price target from $225 to $245.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 1:45 pm

KURA

Scotiabank analyst George Farmer has initiated coverage on Kura Oncology (NASDAQ:KURA) with a Sector Perform rating and a price target of $10.5.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 1:44 pm

BMEA

Scotiabank analyst George Farmer has initiated coverage on Biomea Fusion (NASDAQ:BMEA) with a Sector Outperform rating and a price target of $41.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 1:43 pm

SNDX

Scotiabank analyst George Farmer has initiated coverage on Syndax Pharmaceuticals with a Sector Outperform rating and a price target of $39.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 1:42 pm